Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
5/20/24 Esperion Therapeutics (ESPR) Nexletol for Dyslipidemia / Hypercholesterolemia Subscribers Only Subscribers Only Subscribers Only
5/17/24 Viatris (VTRS) Pretomanid for Tuberculosis Subscribers Only Subscribers Only Subscribers Only
5/16/24 Eli Lilly (LLY) Efsitora alfa for Diabetes Mellitus, Type II Subscribers Only Subscribers Only Subscribers Only
5/13/24 Novo Nordisk (NVO) Mim8 for Hemophilia A Subscribers Only Subscribers Only Subscribers Only
5/11/24 Cardurion Pharmaceuticals CRD-740 for Chronic Heart Failure - Reduced Ejection Fraction (Chronic HFrEF) Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
03/19/24 Subscribers Only Subscribers Only Company - Analyst/R&D Update
04/09/24 Subscribers Only Subscribers Only Company - Analyst/R&D Update
04/15/24 Subscribers Only Subscribers Only Partnership - Acquisition Completion
04/15/24 Subscribers Only Subscribers Only Partnership - Acquisition Completion
04/18/24 Subscribers Only Subscribers Only Company - Analyst/R&D Update